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Simple Summary: The central dogma of RNA biology was traditionally governed by the transcrip-
tion of DNA into messenger RNA (mRNA) followed by translation into protein. As additional
functions of RNA were discovered, it became clear that there were many species of RNA, and many
of those species were multifunctional with roles outside of coding for protein. One such area of
discovery was the ability to form circular RNAs (circRNAs) that have been shown to be important in
a wide range of cellular processes and as such are important in health and disease. These functions
broadly include the modulation of gene expression, facilitation of protein–protein interactions and
protein translation. It is important to understand how the dysregulation of these processes are
involved in cancer progression and the avenues this may open for the targeting or overexpression of
circRNAs as novel therapeutics.
Abstract: The majority of RNAs transcribed from the human genome have no coding capacity and
are termed non-coding RNAs (ncRNAs). It is now widely accepted that ncRNAs play key roles in
cell regulation and disease. Circular RNAs (circRNAs) are a form of ncRNA, characterised by a
closed loop structure with roles as competing endogenous RNAs (ceRNAs), protein interactors and
transcriptional regulators. Functioning as key cellular regulators, dysregulated circRNAs have a
significant impact on disease progression, particularly in cancer. Evidence is emerging of specific
circRNAs having oncogenic or tumour suppressive properties. The multifaceted nature of circRNA
function may additionally have merit as a novel therapeutic target, either in treatment or as a novel
biomarker, due to their cell-and disease-state specific expression and long-term stability. This review
aims to summarise current findings on how circRNAs are dysregulated in cancer, the effects this
has on disease progression, and how circRNAs may be targeted or utilised as future potential
therapeutic options.
Keywords: circRNA; ceRNAs; molecular biology of cancer; miRNAs; fusion circRNA; exosomal
circRNA; biomarkers; circRNA therapeutics
1. Introduction
Cancer affects approximately 5% of the population in Western countries and, despite
an increasing five-year relative survival rate in the last decade, still accounts for ~14.6% of
all human deaths [1]. Understanding the molecular biology underlying the mechanistic
causes of cancer is an area of intense research due to the impact cancer has on society and
the sheer complexity of cancer biology. Cancer is often described as the transformation of
normal cells to malignancy, which requires sequential mutational damage to the cellular
genome, resulting in the downstream activation of oncogenes or inactivation of tumour
suppressor genes [2]. Furthermore, aberrations in epigenetic processes have been shown to
be involved in the initiation and progression of cancer through altered gene function of
oncogenes [3,4]. Epigenetic processes that cancer can reprogram include histone modifica-
tions, DNA methylation, RNA modification and non-coding RNAs. The broad nature of
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this disease results in the need for understanding numerous different signalling pathways,
gene expression profiles and protein–protein interactions. Decades of cancer research
has led to a deep understanding of the molecular mechanisms behind a large number of
cancer-related processes. However, to date, research pertaining to the role of noncoding
RNAs (ncRNAs) in cancer is less established. NcRNAs, comprise the majority of the RNA
transcribed from the genome, and their role in cancer is far less elucidated than coding
transcripts and their subsequent proteins. Nevertheless, it is now recognised that ncRNAs
perform major regulatory roles within the cell and are widely implicated in cancer biology.
Circular RNAs (circRNAs) are a subset of ncRNAs, characterised by their closed loop
structure, that have recently been identified as important factors in the development of var-
ious diseases. The abundant and dynamic nature of circRNA expression has highlighted
the capability of circRNAs to be involved in many molecular processes. In particular,
circRNAs have been shown to be aberrantly expressed in a multitude of different can-
cers and furthermore can be involved in the regulation of tumourgenesis through RNA
sponging, protein interaction scaffolding, mRNA transcription regulation and protein
translation [5]. Furthermore, circRNAs are often expressed in a tissue- or condition-specific
manner, with these properties correlating with their importance in cancer [6]. This review
aims to summarise current research on circRNAs and their multifunctional roles in the
molecular biology of cancer.
2. circRNA Biogenesis
circRNAs are structurally defined by a characteristic covalently closed loop structure
that is primarily derived through the backsplicing of canonical splice sites [7]. Flanking
inverted repeats, Trans-acting RNA binding proteins (RBPs) and long flanking introns act
as backsplice initiation sites (Figure 1). Backsplicing functions through joining the 3′ splice
donor site to the upstream 5′ splice acceptor site resulting in a closed circRNA transcript.
The process of backsplicing is generally coupled with canonical splicing, as many circRNAs
are formed from internal exons of pre-mRNAs. The generation of circRNAs can arise from
exons or introns through a number of different pathways. Mammalian exonic circRNA
formation has two distinct mechanisms, “direct backsplicing” (Intron-pairing) or “exon
skipping” (Lariat driven) [8]. Direct backsplicing is considered the primary mechanism of
exonic circRNA generation and involves the standard splicing of two introns, followed by
the base pairing of flanking intronic inverted repeats. Subsequently, the 5′ intron branch
point attacks the splice donor within the 3′ intron. The 3′ intron in turn repeats this
process, attacking the 5′ splice acceptor, forming the circRNA. Exon skipping involves the
alternative splicing of exons resulting in the formation of a lariat. The lariat intermediate
RNA is often degraded. However, in some cases, it can be further spliced, removing the
introns, increasing the proximity of inverted repeat backsplice sites, allowing circularisation
and thus forming an exonic circRNA [9].
Intronic circRNA genesis follows a broadly similar mechanism, with circRNA forma-
tion promoted through proximal intron splice sites, forming a lariat intron. Subsequent
evasion of debranching and degradation allows the 3′ tail of the RNA lariat to be removed
increasing stability of the circRNA [10].




Figure 1. Models of circRNA biogenesis. (A). Lariat driven formation. Backsplicing occurs forming 
a lariat containing introns and skipped exons. The introns can later be spliced out leaving an 
ecircRNA. (B). Intron-pairing driven biogenesis. Complementary flanking introns lead to base pair-
ing bringing splice sites in close proximity promoting circularisation. (C). RBP driven circularisa-
tion. RBPs through binding to the linear transcript bring splice sites in closer proximity facilitating 
further factors in promoting circularisation. (D). Intronic circRNA biogenesis. circRNA formation is 
promoted by a range of cis and trans factors leading to formation of an RNA lariat, further pro-
cessing can remove the 3′ tail forming ciRNAs. 
Intronic circRNA genesis follows a broadly similar mechanism, with circRNA for-
mation promoted through proximal intron splice sites, forming a lariat intron. Subsequent 
evasion of debranching and degradation allows the 3′ tail of the RNA lariat to be removed 
increasing stability of the circRNA [10]. 
3. Competitive Endogenous RNAs and Cancer 
circRNAs have the potential to act as key competitive endogenous RNAs (ceRNAs) 
of miRNAs and other small regulator RNAs, and as such may be crucial regulators in 
cancer. Research has previously focused on the direct interactions between miRNAs and 
target mRNA dysregulation in cancer, however, the interactions between ncRNAs regu-
lating these processes further upstream is still relatively unexplored. 
Small regulatory RNAs are a class of RNAs that include endogenous microRNAs 
(miRNAs), small interfering RNAs (siRNAs) and PIWI-interacting RNAs (piRNAs). 
miRNA biogenesis involves the cleavage of imperfect ~33 nt RNA hairpins into pre-
miRNA stem-loops by Drosha and associated co-factors forming the Microprocessor com-
plex (Figure 2) [11]. Alternatively, splicing of pri-miRNA transcripts can form mirtrons 
that mimic pre-miRNAs and allow downstream processing without Microprocessor com-
plex cleavage [12]. Nuclear pre-miRNAs are exported and further processed in the cyto-
plasm by Dicer resulting in a mature miRNA/miRNA duplex. One strand of the miRNA 
Figure . biogenesis. (A). Lariat driven formation. Backsplicing occurs forming a
lariat containing introns a d skipped exons. The introns can later be spliced out leaving an ecircRNA.
(B). Intron-pairing driven biogenesis. Complementary flanking introns lead to base pairing bringing
splice sites in close proximity promoting circularisation. (C). RBP driven circularisation. RBPs through
binding to the linear transcript bring splice sites in closer proximity facilitating further factors in
promoting circularisation. (D). Intronic circRNA biogenesis. circRNA formation is promoted by a
range of cis and trans factors leading to formation of an RNA lariat, further processing can remove
the 3′ tail forming ciRNAs.
3. Competitive Endogenous RNAs and Cancer
circRNAs have the potential to act as key competitive endogenous RNAs (ceRNAs) of
miRNAs and other small regulator RNAs, and as such may be crucial regulators in cancer.
Research has previously focused on the direct interactions between miRNAs and target
mRNA dysregulation in cancer, however, the interactions between ncRNAs regulating
these processes further upstream is still relatively unexplored.
Small regulatory RNAs are a class of RNAs that include endogenous microRNAs (miR-
NAs), small interfering RNAs (siRNAs) and PIWI-interacting RNAs (piRNAs). miRNA bio-
genesis involves the cleavage of imperfect ~33 nt RNA hairpins into pre-miRNA stem-loops
by Drosha and associated co-factors forming the Microprocessor complex (Figure 2) [11].
Alternatively, splicing of pri-miRNA transcripts can form mirtrons that mimic pre-miRNAs
and allow downstream processing without Microprocessor complex cleavage [12]. Nuclear
pre-miRNAs are exported and further processed in the cytoplasm by Dicer resulting in
a mature miRNA/miRNA duplex. One strand of the miRNA duplex associates with a
i ISC co plex allowing dow stream posttranscriptional repression [13]. miRNAs an
function as both activators and suppressors of cancer. For inst ce, miR-15a and miR-16-1
ve asso iations as tumour suppressor genes through the targeting of onc genic mRNAs
in chronic lymphocytic ukaemia (CLL), as th loss of these miRNAs is ob erved in ~70%
of CLLs [14]. While miRNAs express d from miR-17-92 clust r are classifie as oncomiRs,
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due to their overexpression in a range of cancers, linked to the suppression of tumour
suppressor genes [15].
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“sponge”. This sponging activity has been shown to be an essential function of some circR-
NAs [16]. In order to act as a miRNA sponge, the circRNA contains repeating seed-targets 
complementary to the miRNA sequence. The miRNA binds to the seed target within the 
circRNA, preventing binding to the canonical mRNA target, instead being sequestered 
and ultimately degraded [17]. The reduction of miRNA activity on downstream targets 
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rectly regulating oncogenes or tumour suppressor genes. For example, miRNA sponging 
activity of the circRNA ciRS-7 against miR-7 results in suppressed miR-7 activity and in-
creased levels of miR-7 targets [18]. ciRS-7 was the first circRNA identified as a ceRNA 
and has over 70 binding sites for miR-7. Accordingly, increased levels of ciRS-7 in cancer 
can lead to efficient inhibition of miR-7 functionality. This in turn leads to increased ex-
pression of miR-7 target oncogenes Focal adhesion kinase (FAK), Insulin Like Growth Fac-
tor 1 Receptor (IGF1R), Epidermal growth factor receptor (EGFR) and Yin Yang 1 (YY1) 
resulting in increased proliferation, EMT and migration. Upregulation of ciRS-7 has been 
found in a range of cancers including gastric, lung and colorectal [19]. Additionally, 
within hepatoblastoma, circ-STAT3 increases STAT3 expression through the sponging of 
Figure 2. Model of miRNA sponging pathways. (A) circRNA sponging occurs upon expression of
circRNA containing multiple miRNA target regions that function to sequester miRNA resulting in
mRNA target upregulation. (B) The canonical RNAi pathway sees miRNA being loaded into the
RISC complex allowing targeted degradation of corresponding mRNA resulting in down regulation.
(C) miRNA sponging can be induced artificially through the expression of a miRNA cassette that
contains multiple miRNA target sites for the miRNA of interest. Reporter genes are often included
for selection or screening.
The regulation of iR A activity can occur via the binding of miRNAs to a miRNA
“sponge”. This sponging activity has been shown to be an essential function of some
circRNAs [16]. In order to act as a miRNA sponge, the circRNA contains repeating seed-
targets complementary to the miRNA sequence. The miRNA binds to the seed target within
the circRNA, preventing binding to the canonical mRNA target, instead being sequestered
and ultimately degraded [17]. The reduction of miRNA activity on downstream targets
can affect cancer pathogenesis through the regulation of signalling pathways or by directly
regulating oncogenes or tumour suppressor genes. For example, miRNA sponging activity
of the circRNA ciRS-7 against miR-7 results in suppressed miR-7 activity and increased
levels of miR-7 targets [18]. ciRS-7 was the first circRNA identified as a ceRNA and
has over 70 binding sites for miR-7. Accordingly, increased levels of ciRS-7 in cancer
can lead to efficient inhibition of miR-7 functionality. This in turn leads to increased
expression of miR-7 target oncogenes Focal adhesion kinase (FAK), Insulin Like Growth
Factor 1 Receptor (IGF1R), Epidermal growth factor receptor (EGFR) and Yin Yang 1 (YY1)
resulting in increased proliferation, EMT and migration. Upregulation of ciRS-7 has been
found in a range of cancers including gastric, lung a d colorect l [19]. Additionally,
within hepatoblast ma, circ-STAT3 increases STAT3 expression through the sponging
of miR-29a/b/c/-3p, with this increase contributing to liver malignancy. Interestingly,
through its role as a ceRNA, circSTAT3 regulates levels of its parental linear transcript,
although most circRNAs do not regulate their parental transcript [20]. There have been
over 128 circRNA-miRNA sponging interactions identified that dysregulate oncogenes and
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tumour suppressor genes, illustrating the miRNA sponging ability of circRNAs can have a
profound impact on cell based molecular biology, resulting in cancer pathogenesis.
4. Transcriptional Regulation and Cancer
Transcriptional regulation of circRNA begins with the biogenesis of circRNAs and its
fundamental co-transcriptional nature. There is a negative correlation between linear and
circRNA expression when the majority of exons are circularised, suggesting competition
between the linear and the circular transcripts for the spliceosomal machinery [21]. Typi-
cally, circRNA abundance is low, however hundreds of circRNAs identified within mouse
and human CNS have been shown to be expressed several folds higher than their linear
isoform [22]. circRNAs can directly regulate transcription of the linear isoform through
variable splicing, involving the preferential splicing of alternative splice sites utilising
different splicing methods and mRNA isomers. For example, the co-transcriptional produc-
tion of circMBL competes with its own Muscleblind (MBL) pre-mRNA for the spliceosomal
machinery. Conserved MBL protein binding sites are found on the flanking intronic se-
quences of circMBL. Therefore MBL can stimulate circRNA biogenesis through binding and
bridging of flanking introns containing MBL binding sites- including its own circMBL and
decreasing mRNA levels [21]. Furthermore, the interaction between RNA-binding proteins
(RBP) and circRNAs can impact splicing due to the tight regulation of RBPs bound near
splice sites. During human epithelial–mesenchymal transition (EMT), circRNA production
is dynamically regulated by the alternative splicing factor Quaking (QKI). QKI functions
similarly to MBL through the binding of QKI binding motifs flanking circRNA-forming
exons that promote circRNA formation in transcripts that are predominantly linearly
spliced [23].
An emerging area of study is the interaction between circRNAs and RNA binding
proteins (Figure 3). These interactions have been shown to control gene expression. Hu-
man antigen R (HuR), a protein involved in cellular proliferation and development is
regulated by circAGO2 through the recruitment of HuR to the 3′-UTR of target genes
resulting in downstream proliferation and pathogenesis in gastric cancer cells [24]. Intron-
containing circRNAs (EIciRNAs) promote the transcription of parental genes, which is
believed to occur via holding RNA–RNA interactions between U1 snRNA and EIciRNA,
enhancing interactions with Poll II transcription complex, thereby promoting parental gene
expression [25].
A further mechanism of circRNA regulation of transcription occurs via induction
of DNA hypomethylation in the promoter region of the parental gene or by regulating
intronic enhancers. The regulation of the FLI1 gene in the development of breast cancer
occurs via the FECR1 circular RNA interacting with the FLI1 promoter through extensive
demethylation, promoting metastasis [26].
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that may have roles in cancer. For instance, an 87 amino acid long peptide from the 
circRNA formed from the lnc LINC-PINT suppresses glioblastoma proliferation, poten-
tially through interactions with the Polymerase-associated factor 1 (PAF1) complex inhib-
iting oncogene transcriptional elongation [28]. Several other small peptides from circR-
NAs have been described with putative roles in cancer ranging from acting as a decoy for 
protein degradation mechanisms, increasing levels of the canonical protein [29], and acti-
vation of cancer signalling pathways, including Hippo and Wnt [30]. 
6. circRNA Facilitated Protein Interactions in Cancer 
Other roles of circRNAs are mediated via protein interactions, including but not lim-
ited to sponging, forming scaffolds or decoys. circRNAs due to their covalently closed 
ring structure have the potential to form different RNA 3D structures compared to their 
linear transcripts, in turn potentially leading to completely different binding partners and 
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5. circRNAs and Translation
Alth ugh class fied as ncRNAs, the is evidence that certain circRNAs are able to
be translated under certain conditions, although this is still controversial. circRNAs have
in proof-of-principle experiments been shown to lead to translation of p tein, and th s
may occur naturally in tissu s that have higher levels of circRNA expression, namely
muscle and neuronal [27]. Several studies have identified small peptides formed from
circRNAs th t may have roles in cancer. For instance, an 87 amino acid long peptide
from the circRNA formed from the lnc LINC-PINT suppresses glioblastoma proliferation,
potentially through interactions with the Polymerase-associated factor 1 (PAF1) complex
inhibiting oncogene transcriptional elongation [28]. Several other small peptides from
circRNAs have been described with putative roles in cancer ranging from acting as a
decoy for protein degradation mechanisms, increasing levels of the canonical protein [29],
and activation of cancer signalling pathways, including Hippo and Wnt [30].
6. circRNA Facilitated Protein Interactions in Cancer
Other roles of circRNAs are mediated via protein interactions, including but not
limited to sponging, forming scaffolds or decoys. circRNAs due to their covalently closed
ring structure have the potential to form different RNA 3D structures compared to their
linear transcripts, in turn potentially leading to completely different binding partners and
novel interactions [31]. As a key role of circRNAs, it is therefore unsurprising that these
interactions are found to be dysregulated in cancer.
Through these protein interactions, circRNAs are capable of widespread cellular dys-
regulation, for instance through epigenetic-mediated regulation of oncoproteins. As men-
tioned previously, the proto-oncoprotein FLI1 has been found overexpressed in breast
and lung cancer, correlating with a poor prognosis. FLI1 overexpression has been linked
to the function of a novel circRNA: circFECR1 [26]. circFECR1 binds to the promoter of
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DNA methyltransferase 1 (DNMT1) and recruits the Tet Methylcytosine Dioxygenase 1
(TET1) protein, TET1, through its demethylase activity, demethylates the CpG regions of
the DNMT1 promoter, resulting in decreased DNMT1 transcription and therefore decreased
protein levels, leading to demethylation of FLI1 DNA, enhancing its expression. Through
the binding and recruitment of TET1, circFECR1 has the potential to be a master regulator
in breast cancer, aiding in oncogenesis.
A further key example of circRNA-protein interactions contributing towards oncogen-
esis is circDNMT1 expression in breast cancer. Cells with high levels of circDNMT1 have a
higher senescence induction tolerance, allowing further replicative cycles and therefore
promoting tumuorigenesis. Mechanistically, circDNMT1 binds to the protein Auf1. circD-
NMT1 through its binding to Auf1 leads to its nuclear translocation, preventing its usual
cytoplasmic binding to DNMT1 mRNA, thereby leading to increased DNMT1 stability
and therefore increased translation of DNMT1. Increased levels of DNMT1 enhance p53
promoter methylation in turn decreasing p53 transcription and aiding tumour proliferation
and survival [31].
circRNAs can conversely protect against and negatively regulate oncogenesis through
specific protein interactions. circZKSCAN1 levels are reduced in hepatocellular carcinoma
(HCC) through the activity of QKI5 and this reduction correlates with poorer survival rates.
circZKSCAN1 binds to the protein FMRP acting as a competitive inhibitor, which prevents
FMRP activating the downstream target CCAR1 which in turn prevents CCAR1 mediated
activation of Wnt/β-catenin [32]. Furthermore, overexpression of circZKSCAN1 can lead
to the inhibition of in vivo HCC growth in mouse xenograft models, highlighting the
potential therapeutic value.
7. Fusion circRNAs in Cancer
The role of chromosomal translocations leading to the production of fusion gene
products is well-known phenomenon in cancer, with examples including BCR-ABL and
PML-RARA [33] with the resulting fusion protein contributing to or even driving oncogene-
sis. Recently evidence has emerged of chromosomal translocations leading to the formation
of novel fusion circRNAs, which can drive oncogenesis. Screenings of clinical samples
with known chromosomal translocations, including PML-RARα and MLL-AF9, identified
several new fusion circRNAs. Interestingly, the fusion circRNAs formed showed variation
from patient to patient, even if the patients had the same chromosomal translocation [34].
Furthermore, analysis of several fusion circRNAs found active roles in tumuorigenesis,
rather than by-products of the initial translocation. These fusion circRNAs were artificially
expressed in non-chromosomal translocated cells, allowing any changes in cell pheno-
type to be assigned to the circRNA, independent of the fusion protein or linear transcript.
Cells had increased resistance to contact inhibition and showed increased proliferation
upon activation of signalling pathways. Notably, targeted knockdown of specific fusion
circRNAs expressed endogenously induced apoptosis, implicating these fusion circRNAs
in cellular survival and as a potential cancer therapy target [34,35]. Furthermore, research
has shown that the introduction of chromosomal translocations via CRISPR-Cas9 sys-
tems also leads to the formation of novel fusion circRNAs, implying circRNAs are likely
produced from translocations events more readily than previously thought, with several
different circRNAs produced from each translocation event, although functionality was
not determined [36].
8. Exosomal circRNAs in Cancer
Exosomes are extracellular vesicles averaging around 40–160 nM in diameter, sur-
rounded by a lipid bilayer. Discovered in the 1980s, their original role was thought to
be restricted to cellular waste disposal. Since then, however, they are thought to func-
tion as key cellular messengers, transporting molecules including proteins, mRNA and
metabolites all around the body [37]. As part of a cellular process, they have been found
to be dysregulated during oncogenesis, aiding in communication between cancer cells
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and contributing to the tumour microenvironment. These exosomes have been designated
tumour derived exosomes (TEXs) and deliver a range of factors, aiding growth, metastasis
and other pro-oncogenic functions to cells and metastatic sites [38].
circRNAs have the potential to be key components of exosomes due to their inherent
stability and multiple regulatory roles, with initial studies identifying the contents of tu-
mour cell exosomes to vary from those of a healthy individual. Of particular note is the
ratio of circRNAs to their linear counterparts in the tumour cell exosomes, which was up
to six-fold higher, suggesting higher levels of incorporation against the natural cellular
circBiome and therefore specific selection [39]. Furthermore, the exosome circBiome con-
tents varies from the parent cells, once again suggesting specific incorporation of select
circRNAs, over just random incorporation from the general population. However, it must
be noted that circRNA enrichment in the exosomes could be due to their inherent stability
and resistance to exonucleases, rendering them more resistant to degradation [40]. Finally,
although there is potential for these exosomal circRNAs to simply be artifacts from an RNA
disposal mechanism, numerous studies have found that RNAs packaged into exosomes
have functionality in recipient cells. In addition, specific enrichment patterns suggest a
form of selection, with similar studies in lncRNAs showing low abundance lncRNAs are
highly enriched in exosomes, compared to higher abundance lncRNAs [41,42]. If exosomal
circRNAs are just a mechanism of removal, it is likely the levels of RNAs within exosomes
would reflect levels within the cell due to non-specific removal. However, current data
does not suggest this.
Already there is functional analysis of specific exosomal enriched circRNAs in cancer,
one study identified circPSMA1 as a circRNA enriched in cancer cell derived exosomes.
Functional analysis showed this circRNA acted as a miRNA sponge, targeting the tumour
suppressive miR-637, in turn leading to increase in Akt1 expression, and increases in
β-catenin and cyclin D1 [43]. Due to circPSMA1 localisation to the exosomes, this pro-
oncogenic mechanism was not just limited to the immediate area, with cells exposed
to these circPSMA1 exosomes showing increased migration and proliferation in a dose-
dependent manner.
circRNAs in exosomes can also aid in oncogenesis through mechanisms outside the
primary hallmarks of cancer, with roles identified in the emerging hallmarks, namely
glucose metabolism. Cancer cells have increased metabolic activity, and advanced cancer
is often associated with cachexia. It is theorised this state can be due to increased levels of
brown adipose tissues (BATs) formed from white adipose tissues (WAT) [44] which leads to
increased energy expenditure. One study found gastric cancer patients had increased levels
of BAT and proposed exosomal circRNAs could contribute, inducting BAT formation at
sites far away from the primary tumour. Plasma exosomes had increased levels of ciRS-133.
Moreover, levels of ciRS-133 correlated with BAT levels. The exosomes allowed the delivery
of circRS-133 to the adipose sites, followed by increased sponging of miR-133. This in turn,
led to the increased expression of PRDM16, a transcription factor, and increased maturation
rates in adipocyte precursors [45].
Due to the ability of exosomes to migrate and play key roles as messengers, exosomes
can particularly contribute to metastasis. Thereby, exosomal circRNAs also have the
potential to aid in the formation of metastatic tumours, with the original primary tumour
secreting pro-oncogenic circRNAs into exosomes to help prime a pre-metastatic niche in
secondary locations around the body. A clinical example of these exosomal circRNAs
playing a role in promoting metastasis would be circIARS. circIARS was found to be
upregulated in pancreatic cancer patients’ tissues and furthermore enriched in exosomes
found in the blood plasma. Higher levels of circIARS correlated with a poorer prognosis
in patient survival and increased chance of metastasis from the primary tumour. Further
experiments found exosomal circIARS was taken up by HUVEC cells at secondary sites,
which led to increases in the permeability of the endothelial cells, aiding in the formation
of metastatic sites. circIARS, once at the secondary sites, binds miR-122, in turn leading
to increased levels of RhoA, increased F-actin and decreased ZO-1 to aid in endothelial
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cell monolayer permeability, thereby aiding metastatic spread [46]. Further, in vivo mouse
work further suggested elevated circIARS can promote metastasis of tumours.
9. circRNAs as Potential Biomarkers and Therapeutics
The potential of circRNAs as biomarkers and therapeutics has gained significant
interest in recent years due to their stability and specificity to certain diseases. Due to
their closed structure, circRNAs are resistant to many cellular RNA decay mechanisms.
Many studies have identified circRNAs to be specifically dysregulated or enriched in
specific cancers. For instance, circPDE8A was found to be upregulated in exosomes
released from pancreatic cancer cells, and through sponging of miR-338, it leads to the
activation of MACC/MET/ERK and AKT pathways promoting invasion [47]. Of particular
note is that the authors found the circRNA to be correlated with the severity of disease and
survival rates, allowing the potential for future screens to indicate prognosis through use
of the circRNA as a biomarker.
This excretion of circRNAs into exosomes is of particular interest if these circRNAs
are excreted into the serum, plasma and blood, allowing non-invasive detection. Stud-
ies have already identified that circRNAs can be highly expressed in the saliva and the
blood, allowing relatively non-invasive collection. Moreover, coupled with specificity
for specific diseases and high stability, circRNAs have the potential to be ideal clinical
biomarkers [48,49]. circRNAs have even been found to be detectable in patient urine [50].
Additionally, as previously discussed, several primary tumours excrete circRNAs in exo-
somes, aiding the establishment of metastatic sites. Metastasis is estimated to be responsible
for 90% of cancer fatalities, often only detected past the point of treatment [51]. Monitoring
of exosomes for known metastatic-promoting circRNAs would potentially allow for the
detection of metastatic tumours early on in disease, allowing treatment [52]. Moreover,
further studies are needed to investigate the specificity of circRNA dysregulation through-
out stages of tumour development. Dysregulated circRNAs have been found to differ
between the primary tumour site and any secondary sites. For instance, studies have
found differentially expressed circRNAs in ductal carcinoma in situ (DCIS), the initial
tumour site, compared to invasive ductal carcinoma (IDC) where the cancer has infiltrated
surrounding tissue [53]. Interestingly, several conserved dysregulated circRNAs were also
found between the DCIS and IDC tissues, implying that, despite circRNA dysregulation
being highly specialised, there is the potential for biomarkers using a select few circRNAs.
Likewise, there is evidence that circRNAs may be more conserved between primary and
secondary sites than mRNAs, although whether this is a result of a consistent expression
pattern or the increased stability of circRNAs has not yet been elucidated [54].
Already, levels of specific circRNAs correlate with severity of the disease and even
survival rates. Three circRNAs are derived from the PTGR1 gene, with increased levels
in all three correlating with a poorer prognosis in HCC patients [55]. While increased
levels of another, circPRMT5, were also associated with a poorer survival rate in bladder
cancer [56]. Interestingly, both circRNAs were found to be upregulated in the tumour
exosomes, once again implying circRNAs are specifically dysregulated in disease states
and selected for exosomal packaging. This excretion into exosomes from the original
tumour site would aid non-invasive detection of tumours and could be used for quick and
regular screenings.
Given circRNA specificity in established cancers and metastatic tumours, there is also
the potential for circRNA biomarkers to be used in early detection during pre-malignant
disease states. For instance, several circRNAs have been found to be dysregulated in
colorectcal adenoma that could act as predictive biomarkers for transition to colorectal
cancer (CRC) [57]. Additional studies have also found examples of dysregulated circRNAs
in other pre-cancerous tissues such as oral leukoplakia [58]. However, the most comprehen-
sive and current circRNA sequencing focuses on established cancerous tissues and more
research is needed into pre-malignant detection.
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circRNA expression patterns have also been shown to be modulated under chemother-
apy, with numerous instances of differences between circRNAs in chemoresistant compared
to chemosensitive cells, from lung, to leukaemia and pancreatic [59]. However, whether
these changes in circRNA expression patterns are contributing to chemoresistance or are
simply by-products of other cellular changes requires further investigation. Nonetheless,
initial studies suggest that at least some of these dysregulated circRNA actively promote
chemoresistance. For instance, in cisplatin resistance cells, circRNA sponging of miR-296
leads to increased STAT3 levels, which are associated with increased resistance [60]. Thus,
through monitoring of circRNAs, there is the potential for identifying chemoresistant
cancer cells and tailoring treatment accordingly. Alternatively, circRNAs have also been
identified that can reverse drug resistance. One example is circMTO1, which reverses
drug resistance to monastrol in breast cancer. Monastrol inhibits the function of the pro-
tein Eg5, also known as kinesin-5, and prevents its activity within spindle formation.
This leads to spindle formation arrest and increased apoptosis. However, resistance to
monastrol can occur through mutations in Eg5 preventing drug binding. Research has
found overexpression of circMTO1 can counteract this drug resistance, through binding to
TNF receptor-associated factor 4 (TRAF4), in turn preventing TRAF4-mediated promotion
of Eg5 transcription, leading to reduced Eg5 levels [61], although whether this mechanism
is functionally in vivo is not elucidated.
Additionally, utilising circRNAs ability to sponge miRNA as a means of downregulat-
ing signalling pathways involved in cancer has been investigated as a novel therapeutic
approach. miRNA sponges can be expressed as miRNA sponge cassettes that are formed of
tandem repeats of identical miRNA targeting sites. These cassettes sequester endogenous
cellular miRNAs, impairing the binding of the miRNA to the natural target, thus in-
hibiting the miRNAs post transcriptional regulation activity [62]. Advances in miRNA
sponging lead to the development of artificial circRNA sponges. circmiR was expressed
endogenously in a mammalian model system designed with targets against known cardiac
pro-hypertrophic miR-132 and miR-212. circmiR showed successful antagonism of target
miRNAs and attenuated pathological hypertrophy in a mouse model [63].
A final aspect of circRNAs therapeutic approaches is the potential to act as vectors for
protein expression to aid in the treatment of disease. Currently, the majority of research
is focused on the use of mRNA. However, some of the major hurdles to using mRNA
include its natural instability and ability to trigger an immune response [64]. Evidence
suggests that circRNAs can evade RNA sensing mechanisms within the cell, with the
introduction of exogenous circRNAs leading to significantly less activation of RIG-I and
Toll-like receptors compared to linear RNA [65]. Moreover, due to their stability, exogenous
circRNAs engineered to produce proteins were found to have a protein-producing half-life
of 80–116 h dependent on cell line, compared to 45–50 h using exogenous linear vectors.
This increased half-life not only compensated for the decreased efficiency of translation
associated with circularisation, but led to increased protein yields compared to linear
vectors. However, just as the overall area of protein expression therapy requires further
investigation, so does the use of circRNAs, with particular problems in guaranteeing
circularisation efficiency [66].
10. Conclusions
The study of circRNA dysregulation in cancer is an emerging field that offers exciting
new avenues of research. The multitude of functions that circRNA perform within cellular
biology has shown the breadth of dysregulation that can occur in many cancers and
other disease states. Evidently, these functions are complex and intertwined and have a
profound effect on signalling pathways, transcription and translation when dysregulated.
Many questions remain concerning circRNAs, including the causal factors of dysregulation
and how big a role they may play in driving oncogenesis. The potential to utilise the
intrinsic stability and specificity of circRNAs for diagnostics and treatment in particular
merits further investigation.
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